Skip to main content

Table 7 Budget impact

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

  Overall num. Patients Num. patients treated with efmoroctocog alfa Cost CE (Euro) Cost NE (Euro) Savings (Euro) % Savings
Year 1
 Pediatrics 169 17 11,812,558 11,686,364 126,194 1.1%
 Adults 691 69 172,352,752 169,523,751 2,829,001 1.6%
 Total 860 86 184,165,311 181,210,115 2,955,196 1.6%
Year 2
 Pediatrics 170 26 11,871,934 11,681,691 190,243 1.6%
 Adults 694 104 173,219,079 168,954,248 4,264,831 2.5%
 Total 864 130 185,091,013 180,635,939 4,455,074 2.4%
Year 3
 Pediatrics 171 34 11,931,608 11,676,676 254,932 2.1%
 Adults 698 140 174,089,760 168,374,735 5,715,025 3.3%
 Total 869 174 186,021,368 180,051,411 5,969,957 3.2%
Total
 Pediatrics 510 77 35,616,100 35,044,731 571,369 1.6%
 Adults 2083 313 519,661,591 506,852,735 12,808,856 2.5%
 Total 2593 390 555,277,691 541,897,466 13,380,225 2.4%
\